Avinger, Inc. (NASDAQ:AVGR) Short Interest Update

Avinger, Inc. (NASDAQ:AVGR) was the target of a significant decline in short interest in April. As of April 15th, there was short interest totalling 41,800 shares, a decline of 16.9% from the March 31st total of 50,300 shares. Based on an average daily trading volume, of 53,000 shares, the days-to-cover ratio is presently 0.8 days. Currently, 2.9% of the company’s shares are short sold.

Avinger Price Performance

Shares of AVGR stock traded down $0.20 on Friday, hitting $3.73. The stock had a trading volume of 6,045 shares, compared to its average volume of 17,030. The stock’s 50 day moving average is $3.47 and its 200-day moving average is $3.33. Avinger has a 52-week low of $2.50 and a 52-week high of $18.00.

Avinger (NASDAQ:AVGR) last posted its quarterly earnings data on Wednesday, March 20th. The medical device company reported ($3.93) EPS for the quarter, missing analysts’ consensus estimates of $0.64 by ($4.57). The business had revenue of $1.91 million for the quarter, compared to analysts’ expectations of $2.52 million. Equities research analysts anticipate that Avinger will post -2.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. StockNews.com initiated coverage on shares of Avinger in a report on Wednesday. They set a “hold” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price target on shares of Avinger in a research report on Thursday, March 21st.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.